血清肿瘤标记物联合动态检测在肺癌诊断和监控治疗中的应用

目的探讨血清肿瘤标记物联合动态检测在肺癌患者临床诊断与监控治疗中的应用。方法选取2012年1月至2013年12月收治的80例肺癌患者为研究组,同期收治的80例肺部良性疾病患者为良性组,80例健康体检者为常规组,对三组血清肿瘤标记物联合动态检测,并分析肺癌患者治疗前后血清肿瘤标记物的变化。结果研究组癌胚抗原（CEA）、组织多肽抗原（TPA）、糖分解烯醇酶（NSE）、胚胎抗原153（CA153）和胚胎抗原242（CA242）及细胞角蛋白19片段（CYFRA21-1）含量明显高于良性组和常规组（P〈0.05）,而良性组和常规组比较无差异（P〉0.05）,治疗后患者各项指标含量低于治疗前（P〈0.05）。结论临床中应用血清肿瘤标记物联合动态检测在肺癌诊断中具有重要的应用价值,且对患者的治疗指导也具有明显的优势。

Serum tumor markers combined dynamic detection of lung cancer diagnosis and monitoring of treatment

Objective To investigate the serum tumor markers combined dynamic detection of lung cancer diagnosis and monitoring of treatment. Methods Our hospital in January 2012 to December 2013 were treated 80 cases of lung cancer patients for the study group,earlier admitted 80 patients with benign lung diseases as benign group,80 cases of healthy people for the conventional group,for three groups Serum tumor markers combined motion detection and treatment of lung cancer patients before and after analysis of serum tumor markers. Results The study group carcinoembryonic antigen（CEA）,tissue polypeptide antigen（TPA）,glycolytic enolase（NSE）,embryonic antigen 153（ CA153） and embryonic antigen 242（CA242） and cytokeratin 19 fragment（CYFRA21- 1） were significantly higher than in the benign group and the conventional group（P〈 0. 05）,whereas no difference in the content of the benign group and the conventional group（P 〉0. 05）,the indicators after treatment was significantly lower than before treatment（P〈 0. 05）. Conclusion Serum tumor markers joint motion detection has important applications in diagnosis of lung cancer,and the patient＇s treatment guidance.